InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present at H.C. Wainwright Global Investment Conference
September 2, 2025
Calidi Biotherapeutics (NYSE American: CLDI), announced that CEO Eric Poma, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place Sept. 8-10, 2025, at the Lotte New York Palace Hotel in New York. An on-demand presentation will be available starting Sept. 5 at 7 a.m. ET, highlighting Calidi’s RedTail platform, which […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option
August 22, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted therapies to deliver genetic medicines to distal sites of disease, announced the closing of its underwritten public offering and the full exercise of the underwriters’ over-allotment option for gross proceeds of $6.9 million before deducting commissions and expenses. The Company sold 1,922,764 common stock […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Prices $6 Million Public Offering
August 20, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted therapies to deliver genetic medicines, announced the pricing of an underwritten public offering for gross proceeds of $6 million before expenses. The offering includes about 1.47 million common stock units priced at $2.00 each and about 1.53 million pre-funded warrant units priced at $1.999 […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Q2 2025 Results and Business Highlights
August 11, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted therapies to deliver genetic medicines to metastatic disease sites, reported a Q2 2025 net loss of $5.7 million, or $1.99 per share, compared to a net loss of $7.4 million, or $16.75 per share, in Q2 2024. R&D expenses were $2.6 million versus $2.2 […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Fast Track Designation for CLD-201 in Soft Tissue Sarcoma
July 29, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted genetic medicine delivery therapies, announced that the U.S. Food and Drug Administration granted Fast Track designation to CLD-201 (SuperNova), its allogeneic adipose stem-cell loaded oncolytic virus for treating soft tissue sarcoma. The designation provides opportunities for expedited development, including priority review and accelerated approval. […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces 1-for-12 Reverse Stock Split Effective August 5
July 28, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted genetic medicine delivery platforms, will implement a 1-for-12 reverse stock split of its common stock effective August 5, 2025. Shares will begin trading on a split-adjusted basis on the NYSE American under the existing ticker “CLDI,” with a new CUSIP of 320703 408. The […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar Highlighting RedTail Platform and Oncology Advancements
July 22, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing targeted genetic medicine therapies, will host an investor webinar on July 24, 2025, at 4:15 p.m. ET. Led by CEO Eric Poma, Ph.D., the event will showcase Calidi’s RedTail(TM) platform, a systemically delivered viral therapy designed to treat metastatic tumors by evading immune detection. Preclinical […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in NetworkNewsWire Spotlight on Genetic Medicines
July 11, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech innovator, announced its inclusion in an editorial by NetworkNewsWire titled “Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers.” The article highlights Calidi’s next-generation platform, which uses engineered viruses to deliver genetic therapies directly to primary and metastatic tumors. While oncology is the company’s initial focus, it is […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Raises $4.6 Million Through Warrant Exercise Agreement
July 10, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm developing targeted therapies for genetic medicine delivery, announced a definitive agreement for the immediate cash exercise of outstanding warrants totaling 6,595,000 shares of common stock at a reduced price of $0.70 per share. The transaction is expected to generate approximately $4.6 million in gross proceeds. In […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
July 10, 2025
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) — via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in Editorial Highlighting Breakthrough Genetic Medicine Platform
July 8, 2025
Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company’s precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With global cancer diagnoses expected to reach 35 million annually by 2050, Calidi’s approach represents a potential breakthrough in addressing critical unmet needs. The company’s […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
July 8, 2025
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) — via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter
June 27, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing systemic oncolytic targeted immunotherapies, released a shareholder letter from CEO Eric Poma, PhD, outlining a transformative year for the company. Since Poma’s appointment in April 2025 and the addition of Dr. Guy Travis Clifton as Chief Medical Officer, Calidi has streamlined operations and advanced its […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Taps Biotech Veteran to Lead Next Phase of Growth
June 10, 2025
Calidi Biotherapeutics (NYSE American: CLDI) recently announced the appointment of Eric Poma, PhD, as its new chief executive officer and member of the board of directors. The company was featured in an article that reads, “As Calidi Biotherapeutics continues to pioneer targeted antitumor virotherapies, the appointment of Dr. Poma as CEO represents a strategic move […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Unveils Promising Data on CLD-401 at ASCO 2025
June 5, 2025
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads. The company unveiled promising new data on its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology (“ASCO”) Annual Meeting. The announcement reads, “Calidi has previously demonstrated […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) RTNova Shows Promise in Targeted Tumor Therapy
May 22, 2025
Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The innovative platform not only targets cancer cells effectively but also minimizes harm to surrounding healthy tissues, potentially improving treatment outcomes and reducing side effects. As global cancer […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names Experienced Life Science Leader as New CEO
May 19, 2025
Effective leadership is a cornerstone of organizational success, particularly in the dynamic and high-stakes realm of biotechnology. Recognizing the pivotal role of seasoned leadership, Calidi Biotherapeutics (NYSE American: CLDI) has announced the appointment of Eric Poma, PhD, as its new Chief Executive Officer and member of the board of directors (https://ibn.fm/qMEu4). This strategic transition underscores Calidi’s […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Redtail Virotherapy Platform and Reduces Q1 Losses
May 15, 2025
Calidi Biotherapeutics (NYSE American: CLDI) reported a Q1 2025 net loss of $5.0 million, narrowing from $7.2 million in the prior year, with R&D and G&A expenses also declining. The company highlighted FDA clearance of its IND for CLD-201, an allogeneic stem cell-based immunotherapy for solid tumors, and presented promising Redtail platform data at AACR […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Eyes Game-Changing Approach to Cancer Treatment
May 9, 2025
Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its innovative RTNova platform, which has successfully delivered transient gene-therapy payloads to targeted tumors. In addition, Calidi’s virotherapy demonstrated efficacy in killing more than 60 different tumor cell lines, showcasing the platform’s potential to revolutionize cancer treatment by enabling both tumor destruction and robust […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research
April 30, 2025
Cancer remains one of the deadliest diseases worldwide. Globally, the World Health Organization reports that the number of deaths will surpass 9.7 million in 2024, with a projected 20 million new cancer cases diagnosed; WHO also noted that it anticipates the cancer burden increasing an estimated 77% by 2050 (https://ibn.fm/VfZlY). These numbers underscore the urgency […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research
April 29, 2025
Cancer remains one of the most formidable health challenges worldwide, necessitating relentless research to uncover effective treatments. Continuous scientific inquiry has led to groundbreaking therapies, offering hope to millions. A recent development in this arena is Calidi Biotherapeutics’ (NYSE American: CLDI) announcement of promising preclinical results for its systemic RTNova platform, highlighting the critical role […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances RTNova Platform with IL15 Superagonist Payload
April 28, 2025
Calidi Biotherapeutics (NYSE American: CLDI) announced the selection of IL15 superagonist (IL15-IL15Ra) as the first therapeutic payload for its systemic antitumor virotherapy platform, RTNova. Preclinical data presented at the AACR Annual Meeting show that Calidi’s engineered vaccinia virus can deliver IL15 superagonist directly into the tumor microenvironment, significantly boosting immune response and tumor elimination while […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Grants Inducement Stock Option to New CEO Eric Poma
April 25, 2025
Calidi Biotherapeutics (NYSE American: CLDI) a clinical-stage biotechnology company advancing targeted antitumor virotherapies, announced the approval of an inducement non-qualified stock option grant to new Chief Executive Officer Eric Poma, Ph.D. The grant includes the option to purchase 726,412 shares at an exercise price of $0.469, the closing price of Calidi’s common stock on April […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Eric Poma as CEO to Lead Next Phase of Clinical Growth
April 23, 2025
Calidi Biotherapeutics (NYSE American: CLDI) announced the appointment of Eric Poma, Ph.D., as Chief Executive Officer and member of its Board of Directors, effective Apr. 22. He succeeds Allan Camaisa, who will continue as a Board member. Dr. Poma, a veteran biotech leader, brings over 30 years of experience, including roles at Molecular Templates (NASDAQ: […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar Highlighting Cancer Immunotherapy Pipeline
April 22, 2025
Calidi Biotherapeutics (NYSE American: CLDI) will host a live investor webinar on April 24, 2025, at 4:15 p.m. ET, featuring its new Chief Medical Officer, Dr. Guy Travis Clifton. The event will spotlight Calidi’s stem cell-based delivery platforms for oncolytic virus therapies, including the FDA-cleared CLD-201, which is advancing toward trials for solid tumors. Additional […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Clearance to Begin Trials for CLD-201 in Solid Tumors
April 17, 2025
Calidi Biotherapeutics (NYSE American: CLDI) announced FDA clearance of its Investigational New Drug application for CLD-201, an allogeneic stem cell-based virotherapy targeting solid tumors including breast cancer, head and neck cancer, and soft tissue sarcoma. Backed by preclinical data showing immune system evasion and potent tumor-killing ability, CLD-201 is now cleared to enter clinical development. […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Oncology Expert Dr. Guy Travis Clifton as Chief Medical Officer
April 10, 2025
Calidi Biotherapeutics (NYSE American: CLDI) has named Dr. Guy Travis Clifton as Chief Medical Officer, Consultant and Advisor. The appointment comes as Calidi advances clinical development of CLD-201, a virotherapy for solid tumors, following a recently filed Investigational New Drug application. Dr. Clifton brings over 17 years of oncology and clinical trial expertise, including leadership […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Cancer Platforms, Reports Narrowed Loss for Q4 2024
April 2, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted immunotherapies, reported a reduced net loss of $4.1 million for Q4 2024, down from $8.2 million the prior year. The company highlighted significant progress across its three oncology platforms, including the IND filing for CLD-201 targeting solid tumors and continued clinical development of CLD-101 […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $3.9 Million Offering to Advance Immunotherapy Programs
April 1, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted immunotherapies, closed its previously announced registered direct offering and concurrent private placement with a single institutional investor, raising approximately $3.9 million in gross proceeds. The offering included 3,325,000 shares of common stock and pre-funded warrants for 2,728,000 shares, along with Series G warrants for […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces $3.9 Million Registered Direct Offering and Private Placement
March 28, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company advancing targeted immunotherapies, has entered into a securities purchase agreement with a single institutional investor for a registered direct offering of 3,325,000 shares of common stock at $0.65 per share, or pre-funded warrants in lieu of stock. Concurrently, the company will issue series G warrants to […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Encouraging Progress in Brain Cancer Trial with City of Hope
March 26, 2025
Calidi Biotherapeutics (NYSE American: CLDI) announced promising early results from a phase 1 clinical trial evaluating its CLD-101 investigational agent, a neural stem cell-based oncolytic virotherapy, in collaboration with City of Hope. The trial, targeting recurrent high-grade glioma, is the first to assess multiple weekly intracerebral doses of CLD-101. Fourteen participants have been treated so […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments
March 21, 2025
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of research and development of innovative treatments in the field of immuno-oncology. With cancer being the second leading cause of death globally, the company focuses on harnessing antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) Novel Therapies Show Promise Against Aggressive Cancers
March 14, 2025
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company that is pioneering proprietary technology designed to attack solid tumors, empowering the immune system to combat cancer. The company was featured in a recent article that discussed its platform, which utilizes antitumor virotherapies that selectively infect and kill cancer cells while stimulating the body’s immune […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform
March 12, 2025
Calidi Biotherapeutics (NYSE American: CLDI) recently announced positive preclinical results for its systemic RTNova platform, demonstrating effective delivery of transient gene therapy payloads to targeted tumors. The tumor-specific virotherapy has shown efficacy across more than 60 tumor cell lines, with a unique vaccinia virus strain enveloped in a human cell membrane providing protection in the […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Stands at the Forefront of Integrating New Oncology Therapies
March 5, 2025
Calidi Biotherapeutics (NYSE American: CLDI) is leveraging innovative platforms in a commitment to transform cancer treatment using advanced biotechnology. “The company is pioneering therapies that combine stem cells with antitumor viruses to create powerful cancer treatments. Antitumor viruses or virotherapies selectively infect and destroy cancer cells while sparing normal cells and, when paired with stem […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Pioneers Systemic Virotherapy with RTNova Platform
March 5, 2025
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of developing innovative immunotherapies for cancer treatment. Most recently, the company has captured the spotlight for the development of its proprietary systemic platform, RTNova (https://ibn.fm/Z4pM3). The platform represents a significant advancement in systemic virotherapy, particularly in the utilization of enveloped virotherapies to […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) and OS Therapies (NYSE American: OSTX) to Appear on RedChip’s Bloomberg TV Show
February 28, 2025
Calidi Biotherapeutics (NYSE American: CLDI) and OS Therapies Inc. (NYSE American: OSTX) will be featured on RedChip’s Small Stocks, Big Money™ show, airing on Bloomberg TV this Saturday, March 1, at 7 p.m. ET. Andrew Jackson, CFO of Calidi, will discuss the company’s stem cell-based oncolytic virotherapy platform designed to enhance cancer treatment. Calidi’s lead […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth with Strengthened Financial Position and Cutting-Edge Research
February 25, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is making significant strides in the field of cancer immunotherapy. Known for its innovative approach to antitumor virotherapies, Calidi is focused on harnessing the power of its patented technology that protects and potentiates the virotherapy during administration (extracellular enveloped viruses in its systemic platform and stem […]
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment
February 24, 2025
Cancer continues to be one of the most significant health challenges of our time, with its global impact growing every year. The increasing number of cancer diagnoses and related deaths underscores the urgent need for more effective treatments, including advanced oncology drugs. Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are at the forefront of […]
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Launches “CLD-101” Trial for High-Grade Glioma at Northwestern
February 24, 2025
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted antitumor virotherapies, said Northwestern University/Northwestern Memorial Hospital is recruiting for its Phase 1B/2 clinical trial of “CLD-101” in newly diagnosed high-grade glioma patients. The company completed shipment of the first batch of CLD-101—comprising allogeneic neural stem cells loaded with the oncolytic adenovirus CRAd-S-pk7—to support […]